CRISPR Therapeutics AG (NASDAQ:CRSP) and Soligenix Inc. (NASDAQ:SNGX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||57||0.00||34.37M||-0.46||0.00|
Demonstrates CRISPR Therapeutics AG and Soligenix Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 hightlights the return on assets, net margins and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||60,066,410.35%||-2.6%||-2%|
The Current Ratio of CRISPR Therapeutics AG is 8.3 while its Quick Ratio stands at 8.3. The Current Ratio of rival Soligenix Inc. is 1.4 and its Quick Ratio is has 1.4. CRISPR Therapeutics AG is better equipped to clear short and long-term obligations than Soligenix Inc.
The next table highlights the shown recommendations and ratings for CRISPR Therapeutics AG and Soligenix Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
CRISPR Therapeutics AG’s average price target is $72, while its potential upside is 9.67%.
Institutional and Insider Ownership
Roughly 46.8% of CRISPR Therapeutics AG shares are held by institutional investors while 22.4% of Soligenix Inc. are owned by institutional investors. CRISPR Therapeutics AG’s share held by insiders are 0.4%. Competitively, insiders own roughly 12.6% of Soligenix Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year CRISPR Therapeutics AG was more bullish than Soligenix Inc.
CRISPR Therapeutics AG beats on 9 of the 11 factors Soligenix Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.